Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
基本信息
- 批准号:7849568
- 负责人:
- 金额:$ 155.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-06-20 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Lung carcinoma is the leading cause of cancer-related death in men and women in the United States. Despite advances in understanding the biology of lung cancer and introduction of several novel agents, 5 year survival remains at a dismal 15%. In order to enhance therapeutic strategies, we propose to target aberrant cell signaling in lung cancers with a primary focus on the mTOR pathway. Our program consists of 4 interconnected projects and 3 primary cores. The program projects include exploration of the mammalian target of rapamycin (mTOR) axis proteins and their importance in prognosis in lung cancer (primary aim - project 1), along with translating these biological findings into therapeutic advances in lung cancer patients alone and in combination with docetaxel. Project 2 targets LKB1, a tumor suppressor gene known to be inactivated or mutated in lung cancer, and its role as a key regulator of taxane-sensitivity and TOR pathway signaling. Project 3 examines the synergy between taxanes and farnesyl-transferase inhibitors and studies the mechanisms underlying synergy and resistance to this combination. Project 4 examines the 14-3-3 protein, key regulators of the mTOR axis (especially Akt), while testing a potential application of inhibiting the 14-3-3 function for enhancing lung cancer therapy. The projects are ably supported by an administrative core, a lung pathology and molecular analysis core, and biostatistics core. It contains 3 active clinical trials and assessment of biomarkers from the Neoadjuvant Trial of Chemotherapy Hope (NATCH) being conducted in Spain. The ultimate goal of this program project is three-fold: 1) to enhance efficacy of existing agents (taxanes); 2) to study novel signaling pathways that can be regulated by molecules in clinical trials (farnesyl-transferase inhibitors); 3) to develop completely novel approaches to lung cancer therapy through modulating LKB1 and 14-3-3 functions. Lung cancer is the leading cause of cancer-related death in men and women, both in the U.S. and worldwide. Only 15% of lung cancer patients are alive five years after diagnosis, even with new drugs. The proposed program consists of four interconnected projects, supported by three cores. We hope to improve lung cancer therapy by better understanding how lung cancer cells communicate, through the process called cell signaling. We will study these cell signaling pathways and how several drugs interfere with them, so that cancer cells cannot communicate and reproduce. We will also study tumor samples from a large international clinical trial and from our own clinical trials. We believe that this project can make important advances in determining which patients will do well with which therapies. We also hope to find new drugs that only target cancer cells and their altered signaling pathways, leaving healthy cells alone.
描述(由申请人提供):肺癌是美国男性和女性与癌症相关死亡的主要原因。尽管了解了肺癌的生物学和引入几种新型药物的进步,但5年生存仍然令人沮丧。为了增强治疗策略,我们建议靶向肺癌中异常细胞信号传导,主要关注MTOR途径。我们的计划由4个相互联系的项目和3个主要核心组成。该计划项目包括探索雷帕霉素(MTOR)轴蛋白的哺乳动物靶标及其在肺癌预后的重要性(主要目的-Project -Project 1),以及将这些生物学发现转化为单独的肺癌患者的治疗进展,并与多西他赛结合。项目2靶标LKB1(一种已知在肺癌中被灭活或突变的肿瘤抑制基因,及其作为紫杉烷 - 敏感性和TOR途径信号传导的关键调节剂的作用。项目3研究了紫杉烷和Farnesyl-转移酶抑制剂之间的协同作用,并研究了该组合的协同作用和抵抗力的机制。项目4研究了14-3-3蛋白,MTOR轴的主要调节剂(尤其是AKT),同时测试了抑制14-3-3功能以增强肺癌治疗的潜在应用。这些项目得到了行政核心,肺病理和分子分析核心以及生物统计学核心的支持。它包含3项主动临床试验和对西班牙化学疗法希望(Natch)新辅助试验的生物标志物的评估。该计划项目的最终目标是三个方面:1)增强现有代理的功效(紫杉虫); 2)研究可以在临床试验(Farnesyl-转移酶抑制剂)中通过分子调节的新型信号通路; 3)通过调节LKB1和14-3-3功能,开发了完全新颖的肺癌治疗方法。肺癌是在美国和全球范围内男性和女性与癌症相关死亡的主要原因。诊断后五年,只有15%的肺癌患者即使使用了新药。拟议的计划由四个相互联系的项目组成,并由三个核心支持。我们希望通过更好地理解肺癌细胞如何通过称为细胞信号传导进行肺癌细胞来改善肺癌疗法。我们将研究这些细胞信号传导途径以及几种药物如何干扰它们,以使癌细胞无法进行交流和繁殖。我们还将研究大型国际临床试验和我们自己的临床试验的肿瘤样本。我们认为,该项目可以在确定哪些患者对哪种疗法的情况下取得重要的进步。我们还希望找到仅针对癌细胞及其改变信号通路的新药,而将健康细胞独立。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Fadlo Raja Khuri其他文献
Fadlo Raja Khuri的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Fadlo Raja Khuri', 18)}}的其他基金
Modulation of the mTOR Pathway for Lung Cancer Treatment
调节 mTOR 通路治疗肺癌
- 批准号:
8518499 - 财政年份:2012
- 资助金额:
$ 155.25万 - 项目类别:
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
- 批准号:
8518498 - 财政年份:2006
- 资助金额:
$ 155.25万 - 项目类别:
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
- 批准号:
7625951 - 财政年份:2006
- 资助金额:
$ 155.25万 - 项目类别:
Modulation of the mTOR Pathway for Lung Cancer Treatment
调节 mTOR 通路治疗肺癌
- 批准号:
7109527 - 财政年份:2006
- 资助金额:
$ 155.25万 - 项目类别:
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
- 批准号:
8116326 - 财政年份:2006
- 资助金额:
$ 155.25万 - 项目类别:
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
- 批准号:
7083450 - 财政年份:2006
- 资助金额:
$ 155.25万 - 项目类别:
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
- 批准号:
7250877 - 财政年份:2006
- 资助金额:
$ 155.25万 - 项目类别:
相似国自然基金
NgBR调节法尼基修饰LKB1的细胞膜定位介导脂联素/AMPK信号通路的活化在肝脏胰岛素抵抗发生中的机制研究
- 批准号:82370813
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
IRX3及其突变体经p38 MAPK/KIF5B信号轴促进Kv4.3细胞膜定位的分子机制以及对早期复极综合征的意义研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
IRX3及其突变体经p38 MAPK/KIF5B信号轴促进Kv4.3细胞膜定位的分子机制以及对早期复极综合征的意义研究
- 批准号:82200338
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
信号肽介导的荧光纳米探针亚细胞定位及其应用研究
- 批准号:22164017
- 批准年份:2021
- 资助金额:35 万元
- 项目类别:地区科学基金项目
CD90+软骨前体细胞对颞下颌关节退变软骨的治疗作用及其PTHrP细胞核定位信号调节机理
- 批准号:81920108013
- 批准年份:2019
- 资助金额:248 万元
- 项目类别:国际(地区)合作与交流项目
相似海外基金
Engineering T cells to overcome inhibitory receptor signals that limit the efficacy of adoptive cell therapy against ovarian cancer
改造 T 细胞以克服抑制性受体信号,这些信号限制了过继性细胞疗法对卵巢癌的疗效
- 批准号:
10526155 - 财政年份:2023
- 资助金额:
$ 155.25万 - 项目类别:
DRUG DISCOVERY BY DIRECTED EVOLUTION IN MAMMALIAN CELLS
通过哺乳动物细胞定向进化发现药物
- 批准号:
10644749 - 财政年份:2023
- 资助金额:
$ 155.25万 - 项目类别:
Mitochondrial regulation of nociceptor function
伤害感受器功能的线粒体调节
- 批准号:
10644865 - 财政年份:2023
- 资助金额:
$ 155.25万 - 项目类别:
Cellular and Metabolic Dysfunction in Sepsis-Induced Immune Paralysis
脓毒症引起的免疫麻痹中的细胞和代谢功能障碍
- 批准号:
10724018 - 财政年份:2023
- 资助金额:
$ 155.25万 - 项目类别:
Signaling and metabolic functions of nSMase-2 in hepatic steatosis and onset of insulin resistance
nSMase-2 在肝脂肪变性和胰岛素抵抗发作中的信号传导和代谢功能
- 批准号:
10735117 - 财政年份:2023
- 资助金额:
$ 155.25万 - 项目类别: